Neuronostics raised £3M to advance BioEP, a digital biomarker platform for epilepsy diagnosis and prognosis. The University of Exeter spinout will use the round, co-led by Empirical Ventures and The FSE Group, alongside a £400k Innovate UK Investor Partnerships grant, to fund a planned FDA submission, expand NHS adoption, and extend the platform toward measuring treatment response in pharmaceutical trials.